NEW YORK – Daiichi Sankyo on Thursday announced it had entered into a collaboration with AstraZeneca to evaluate the combination of its experimental HER3-directed DXd antibody drug conjugate, patritumab deruxtecan (U3-1402) in combination with AstraZeneca's TKI osimertinib (Tagrisso) in a two-part Phase I clinical trial for the treatment of patients with advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.